Please assess the completion status of the following clinical trial:

Trial Title: Phase1 Syudy to Evaluate the Safety and PK/PD of Human Antithrombin III

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ages 19 to 40~* Body weight: More than 50kg~* Healthy male subject~Exclusion Criteria:~* Hb\<14g/dL, Hct\<42%~* ATIII hypersensitivity

- Gender: MALE
- Minimum Age: 19 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Antithrombin III (Type: ACTIVE_COMPARATOR): None
- SK Antithrombin III (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).